Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Frances M. Palmieri"'
Autor:
Donald W. Northfelt, David W. Hillman, Winston Tan, R. D. Niedringhaus, P. J. Stella, Albert M. Bernath, E. A. Perez, Muhammad Salim, S. S. Gamini, Frances M. Palmieri, D. M. Anderson
Publikováno v:
Annals of Oncology. 29:2150
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82f424cac7eef184978b0354f52f076d
https://doi.org/10.1093/annonc/mdx811
https://doi.org/10.1093/annonc/mdx811
Publikováno v:
Clinical Journal of Oncology Nursing. 14:326-336
This article reviews clinical data on adjuvant trastuzumab (Herceptin ® , Genentech, Inc.) for patients with HER2-positive early breast cancer. Published articles were searched via PubMed (1985-2009), and abstracts were located from meeting books or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab5aad5c58e96017ff06b60367326e7c
https://doi.org/10.1188/10.cjon.326-336
https://doi.org/10.1188/10.cjon.326-336
Autor:
E. A. Perez, S. S. Gamini, P. J. Stella, Donald W. Northfelt, D. M. Anderson, Muhammad Salim, Frances M. Palmieri, David W. Hillman, R. D. Niedringhaus, Albert M. Bernath, Winston Tan
Publikováno v:
Annals of Oncology. 21:493-497
Background Because of the single-agent activity of irinotecan hydrochloride, combination of irinotecan and docetaxel treatment against metastatic breast cancer (MBC) should be evaluated. Patients and methods Single-stage phase 2 study of irinotecan a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f90063a3a2fb14e5802f3f0399dea54
https://doi.org/10.1093/annonc/mdp328
https://doi.org/10.1093/annonc/mdp328
Autor:
David W. Hillman, David L. Graham, N. A. Le-Lindqwister, Tom R. Fitch, E. A. Perez, Tejal Patel, S. P. Kahanic, Amylou C. Dueck, Frances M. Palmieri, Heshan Liu, L. H. Geeraerts, Todor Dentchev, H. M. Gross
Publikováno v:
Annals of Oncology. 21:269-274
Background: Docetaxel (T; Taxotere) with capecitabine (X) is active against metastatic breast cancer (MBC); bevacizumab (BV) has demonstrated efficacy with taxanes in the first-line setting. This study was conducted to assess the safety and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7147cb837d1d93230c0ab46dea909134
https://doi.org/10.1093/annonc/mdp512
https://doi.org/10.1093/annonc/mdp512
Publikováno v:
Clinical Journal of Oncology Nursing. 13:4-10
The selection of therapy for women with metastatic breast cancer requires consideration of many factors. Multiple treatment options are available, including hormonal therapy, chemotherapy, and biologic therapy. Many issues exist regarding choice of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d31a50d7e6f2c52b8fdca432f7d015fe
https://doi.org/10.1188/09.cjon.s1.4-10
https://doi.org/10.1188/09.cjon.s1.4-10
Publikováno v:
Clinical Journal of Oncology Nursing. 13:11-18
Patients with advanced breast cancer are living longer and receiving multiple lines of chemotherapy; however, they eventually develop resistance to the agents. Two more agents have been approved for the treatment of breast cancer and will provide add
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e8d965b297c2754b3a08e1f5bb367ac
https://doi.org/10.1188/09.cjon.s1.11-18
https://doi.org/10.1188/09.cjon.s1.11-18
Autor:
Frances M. Palmieri, Rebecca B. McNeil, Kyle E Coppola, Xochiquetzal J. Geiger, Ann E. McCullough, Surabhi Amar, Sarah A. McLaughlin, Winston Tan, Edith A. Perez, Judy C. Boughey
Long-term outcomes and hence the role of adjuvant therapy in patients with small (≤1 cm), node-negative breast cancer remain unclear. This study's objective was to evaluate whether human epidermal growth factor receptor (HER)-2 status is an indepen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::437432282a19b41befbe9625f74db392
https://europepmc.org/articles/PMC3227894/
https://europepmc.org/articles/PMC3227894/
Publikováno v:
Clinical journal of oncology nursing. 14(3)
This article reviews clinical data on adjuvant trastuzumab (Herceptin, Genentech, Inc.) for patients with HER2-positive early breast cancer. Published articles were searched via PubMed (1985-2009), and abstracts were located from meeting books or sea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e33b4df73c324f56650fb28cff509aba
https://pubmed.ncbi.nlm.nih.gov/20529794
https://pubmed.ncbi.nlm.nih.gov/20529794
Autor:
Frances M. Palmieri, Cynthia Frankel
Publikováno v:
Clinical journal of oncology nursing. 14(2)
Lapatinib is an oral dual tyrosine kinase inhibitor targeting epidermal growth factor receptor and HER2. Diarrhea and dermatologic adverse events are reported commonly by patients treated with lapatinib. Diarrhea can range from mild to severe based o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07ef43d2300f0fffeabf83c710c3d7b8
https://pubmed.ncbi.nlm.nih.gov/20350896
https://pubmed.ncbi.nlm.nih.gov/20350896
Publikováno v:
Cancer treatment and research. 151
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8abcde8490804743882ea6c4560a0c3c
https://pubmed.ncbi.nlm.nih.gov/19593513
https://pubmed.ncbi.nlm.nih.gov/19593513